Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $1.91 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.